Immix Biopharma (IMMX) Cash & Equivalents (2020 - 2026)
Immix Biopharma (IMMX) posted Cash & Equivalents of $79.3 million for Q1 2026, down 15.63% sequentially from $93.9 million in Q4 2025, and up 397.77% YoY from $15.9 million in Q1 2025.
Immix Biopharma (IMMX) Cash & Equivalents (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Cash & Equivalents for 7 years, with the latest figure at $79.3 million in Q1 2026.
- Quarterly Cash & Equivalents rose 397.77% year-over-year to $79.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.3 million (up 397.77% YoY) and the FY2025 annual result came in at $93.9 million, up 431.21% from the prior year.
- Cash & Equivalents fell to $79.3 million in Q1 2026 per IMMX's latest filing, from $93.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $93.9 million in Q4 2025 and troughed at $11.5 million in Q1 2023.
- A 5-year average of $25.7 million and a median of $17.7 million in 2024 frame the typical range for Cash & Equivalents.
- The widest YoY moves for Cash & Equivalents: up 431.21% in 2025, down 51.62% in 2025.
- Over 5 years, Cash & Equivalents stood at $13.4 million in 2022, then surged by 30.31% to $17.5 million in 2023, then rose by 0.98% to $17.7 million in 2024, then jumped by 431.21% to $93.9 million in 2025, then declined by 15.63% to $79.3 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $79.3 million, $93.9 million, and $15.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 232.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 232.10 Mn |
| Mar 31, 2026 | 79.25 Mn |
| Dec 31, 2025 | 93.93 Mn |
| Sep 30, 2025 | 15.95 Mn |
| Jun 30, 2025 | 11.60 Mn |
| Mar 31, 2025 | 15.92 Mn |
| Dec 31, 2024 | 17.68 Mn |
| Sep 30, 2024 | 19.69 Mn |
| Jun 30, 2024 | 23.98 Mn |
| Mar 31, 2024 | 29.32 Mn |
| Dec 31, 2023 | 17.51 Mn |
| Sep 30, 2023 | 19.58 Mn |
| Jun 30, 2023 | 12.65 Mn |
| Mar 31, 2023 | 11.46 Mn |
| Dec 31, 2022 | 13.44 Mn |
| Sep 30, 2022 | 16.92 Mn |
| Jun 30, 2022 | 18.40 Mn |
| Mar 31, 2022 | 19.06 Mn |
| Dec 31, 2021 | 17.64 Mn |
| Dec 31, 2020 | 391,086.00 |